3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma, Ewing
2
Sarcoma
2
Ovarian Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Rare Diseases
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasms, Connective and Soft Tissue
1
Neoplasms, Connective Tissue
1
Neoplasms, Bone Tissue
1
Neoplasms by Histologic Type
1
Neoplasms
1
Lymphoma, Follicular
1
Lymphoma
1
Kidney Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Ovarian Epithelial
1
Interventions
Ifosfamide
6
X-Rays
5
Phantoms, Imaging
5
Magnetic Resonance Spectroscopy
5
Filgrastim
5
Etoposide
5
Doxorubicin
5
Cyclophosphamide
5
Vincristine
4
Temozolomide
4
Specimen Handling
4
Radiotherapy
4
Nuclear Medicine Department, Hospital
4
Melphalan
4
Thiotepa
3
Irinotecan
3
Biopsy
3
Bevacizumab
3
ulixertinib
2
trioctyl phosphine oxide
2
tipifarnib
2
temsirolimus
2
tazemetostat
2
selpercatinib
2
palbociclib
2
olaparib
2
larotrectinib
2
ivosidenib
2
erdafitinib
2
cixutumumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Neuroectodermal Tumors, Primitive, Peripheral
×
FANG vaccine
×
Clear all
NCT03495921
2023-04-26
VITA
Gradalis, Inc.
Phase 3
Terminated
32 enrolled
13 charts